SCHEMBL4471514

SCHEMBL4471514

COc1cc2c(Oc3ccc(NC(=O)NCCC(C)(C)C)cc3F)ccnc2cc1OCCN1CCOCC1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FLT3 P36888 4/20 0.70
MET P08581 15/20 0.66
AXL P30530 3/20 0.66
KDR P35968 2/20 0.66
PLK4 O00444 1/20 0.66
STK25 O00506 1/20 0.66
CIT O14578 1/20 0.66
AURKA O14965 1/20 0.66
CHUK O15111 1/20 0.66
MUSK O15146 1/20 0.66
EPHB6 O15197 1/20 0.66
MAPK13 O15264 1/20 0.66
MAP3K13 O43283 1/20 0.66
DAPK3 O43293 1/20 0.66
MAP3K7 O43318 1/20 0.66
RIPK2 O43353 1/20 0.66
JAK2 O60674 1/20 0.66
ROCK2 O75116 1/20 0.66
PAK3 O75914 1/20 0.66
CDKL5 O76039 1/20 0.66

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4477122 0.97 FLT3 (0.76) FLT3METAXLKDRPLK4
SCHEMBL4476104 0.93 MET (0.66) FLT3METKDRPDGFRBKIT
SCHEMBL4489364 0.92 FLT3 (0.59) FLT3METAXLKDRPLK4
SCHEMBL4476160 0.91 MET (0.59) FLT3METKDRPDGFRBKIT
SCHEMBL4482846 0.90 FGFR2 (0.68) METKDREGFRPDGFRAFGFR2
SCHEMBL4465009 0.90 FGFR2 (0.68) METKDREGFRPDGFRAFGFR2
SCHEMBL4477100 0.90 FGFR2 (0.60) FLT3METKDRPDGFRBKIT
SCHEMBL13937005 0.90 MET (0.69) FLT3METAXLKDRPLK4
Hydrochloric Acid SCHEMBL4465541 0.89 FGFR2 (0.68) METKDREGFRPDGFRAFGFR2
SCHEMBL4469377 0.89 MET (0.57) FLT3METKDRPDGFRBKIT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7495104-B2 Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors KIRIN BEER KABUSHIKI KAISHA (JP) 2009-02-24 US claimed
US-7495104-B2 Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors KIRIN BEER KABUSHIKI KAISHA (JP) 2009-02-24 US disclosed
US-7495104-B2 Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors KIRIN BEER KABUSHIKI KAISHA (JP) 2009-02-24 US disclosed
US-7495104-B2 Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors KIRIN BEER KABUSHIKI KAISHA (JP) 2009-02-24 US disclosed
US-20050049264-A1 Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors KIRIN BEER KABUSHIKI KAISHA (JP) 2005-03-03 US disclosed
EP-1447405-A1 QUINOLINE OR QUINAZOLINE DERIVATIVES INHIBITING AUTO-PHOSPHORYLATION OF FIBROBLAST GROWTH FACTOR RECEPTORS KIRIN BEER KABUSHIKI KAISHA (JP) 2004-08-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050049264-A1 Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors FGFR1, FGFR2, FGFR3 FLT3 27/4885MET 6/4885AXL 40/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.